ストックスクリーナーアプリを入手
1.54
1.99%
0.03
アフターアワーズ：
1.57
0.03
+1.95%
前日終値:
$1.51
開ける：
$1.51
24時間の取引高:
1.58M
Relative Volume:
0.61
時価総額：
$158.94M
収益：
$32.29M
当期純損益:
$-39.12M
株価収益率:
-4.1973
EPS:
-0.3669
ネットキャッシュフロー:
$-29.51M
1週間 パフォーマンス:
+7.69%
1か月 パフォーマンス:
+31.62%
6か月 パフォーマンス:
+76.28%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.51
$1.64
1週間の範囲:
$1.35
$1.64
52週間の値動き範囲:
$0.6434
$1.805
Maxcyte Inc Stock (MXCT) Company Profile
Compare MXCT vs ABT, MDT, SYK, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.54 | 158.94M | 32.29M | -39.12M | -29.51M | -0.3669 |
ABT
Abbott Laboratories
|
103.10 | 178.40B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
93.95 | 120.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
301.42 | 115.62B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.06 | 65.30B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.82 | 52.35B | 6.30B | 1.07B | 1.09B | 1.8406 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-11 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-08-07 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | 開始されました | Stephens | Overweight |
| 2023-11-29 | 開始されました | Craig Hallum | Buy |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-08-24 | 開始されました | BTIG Research | Buy |
| 2021-08-24 | 開始されました | Cowen | Outperform |
| 2021-08-24 | 開始されました | Stephens | Overweight |
| 2021-08-24 | 開始されました | Stifel | Buy |
| 2021-08-24 | 開始されました | Wedbush | Outperform |
| 2021-08-24 | 開始されました | William Blair | Outperform |
すべてを表示
Maxcyte Inc (MXCT) 最新ニュース
Liontrust Investment Partners Discloses Investment at MaxCyte with 5.03% Stake - TradingView
MaxCyte MXCT Hires Danaher Dealmaker To Drive Growth - StocksToTrade
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock? - Zacks Investment Research
North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity - GlobeNewswire Inc.
MaxCyte (MXCT) Stock Analysis Report | Financials & Insights - Benzinga España
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
MaxCyte's new executive has held strategy, innovation and M&A roles over nearly 25 years. - Stock Titan
MXCT stock holds steady as MaxCyte focuses on cell-therapy growth - ad-hoc-news.de
MXCT stock holds steady as MaxCyte prepares next growth steps - ad-hoc-news.de
MXCT Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 2.42%Share Dilution Risk - vinanet.vn
MaxCyte Inc. (MXCT) Peer Comparison – Compare with Others - valueresearchonline.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and MaxCyte (MXCT) - The Globe and Mail
MaxCyte stock rating held at Neutral by BTIG after Q2 results - Investing.com India
MaxCyte stock rating held at Neutral by BTIG after Q2 results - Investing.com
MaxCyte stock rating held at Neutral by BTIG after Q2 results - Investing.com UK
MaxCyte (MXCT) Q2 2026 Earnings: EPS Comes in Above Forecast in the Latest Reading; Market Reaction - vinanet.vn
MaxCyte (MXCT) Q2 2026 Earnings: EPS Comes in Above Forecast in the Latest Reading; Market Reaction - dars.gov.et
MaxCyte Gets A Genentech Nod, But Revenue Still Comes In Chunks - Finimize
MaxCyte launches base editor off-target nomination assays By Investing.com - Investing.com Nigeria
MaxCyte (MXCT) Earnings Reading: EPS Prints Above Forecast in the Latest Session; Stock Move - vinanet.vn
MaxCyte (MXCT) Earnings Reading: EPS Prints Above Forecast in the Latest Session; Stock Move - dars.gov.et
MaxCyte launches base editor off-target nomination assays - Investing.com
MaxCyte launches base editor off-target nomination assays By Investing.com - Investing.com Canada
MaxCyte launches base editor off-target nomination assays By Investing.com - Investing.com India
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies - The Manila Times
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies - marketscreener.com
MaxCyte launches a gene-editing test that sees population-specific DNA variants - Stock Titan
MaxCyte, Inc. Revenue Breakdown – NASDAQ:MXCT - TradingView
MaxCyte(MXCT) Stock Options Chain | Quotes & News - Moomoo
MXCT Q2 2026 Earnings: Narrower-Than-Expected Loss Marks a 15.97% EPS Beat, Yet Shares Slip 5.04%Earnings Sentiment Score - vinanet.vn
Teleconferência de Resultados do 2T26 da MaxCyte (MXCT): Guidance Reafirmado com a Expansão da Parceria com a Genentech - TradingKey
MaxCyte, Inc. Releases Q2 2026 Results: Cell Engineering Platform Momentum in FocusRevenue Inflection Point - dars.gov.et
MaxCyte (MXCT) Earnings Call Q2 2026: Prognose bekräftigt bei Ausbau der Genentech-Partnerschaft - TradingKey
Conferencia de resultados del T2 de 2026 de MaxCyte (MXCT): Se reafirman las proyecciones a medida que se amplía la alianza con Genentech - TradingKey
MaxCyte (MXCT) Q2 2026 Earnings Call: Guidance Reaffirmed as Genentech Partnership Expands - TradingKey
Stifel Nicolaus Keeps Their Buy Rating on MaxCyte (MXCT) - The Globe and Mail
TD Cowen Maintains MaxCyte(MXCT.US) With Buy Rating - Moomoo
MaxCyte revenue down 15% to USD 7.3M in Q2 2026 - medicalbuyer.co.in
MaxCyte, Inc. $MXCT Shares Acquired by Renaissance Technologies LLC - MarketBeat
Price to sales forward of MaxCyte, Inc. – MUN:MYE0 - TradingView
MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ... - Yahoo! Finance Canada
MXCT Looks 49.6% Undervalued on GF Value™ - GuruFocus
MaxCyte, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
MaxCyte Q2 Earnings Call Highlights - MarketBeat
MaxCyte Q2 Earnings Call Highlights - Yahoo Finance
MaxCyte (NASDAQ:MXCT) Issues Earnings Results - MarketBeat
MaxCyte affirms FY26 sales guidance of $30M-$32M vs estimate - scanx.trade
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: MaxCyte tops Q2 2026 revenue forecast, shares fall - Investing.com
Maxcyte Inc (MXCT) 財務データ
収益
当期純利益
現金流量
EPS
2.23%
2.12%
大文字化:
|
ボリューム (24 時間):